Reactivos e instrumentos para inmunología, biología celular y biología molecular.
 
> DL-Borneol [507-70-0]

DL-Borneol [507-70-0]

Imprimir Imprimir
Por favor conéctese

Referencia orb2893575-100mg

embalaje : 100mg

Marca : Biorbyt


DL-Borneol

SKU: orb2893575

Description

DL-Borneol ((endo)-Borneol) is a natural compound used as an oral bioadjuvant to enhance brain drug delivery. It is applied in research on cardio-cerebral vascular diseases, with studies demonstrating its ability to improve blood-brain barrier permeability in both in vitro and in vivo experimental models.

Research Area

Metabolism Research, Neuroscience, Pharmacology & Drug Discovery

Images & Validation

−
DL-Borneol

Key Properties

−
CAS Number507-70-0
MW154.25
Purity98.61% (May vary between batches)
FormulaC10H18O
SMILES23[C@]12CC[C@](C)([C@@H](O)C1)C2(C)C
TargetGABA Receptor,Endogenous Metabolite
SolubilityH2O:<0.1 mg/mL (Insoluble);DMSO:30 mg/mL (194.49 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (12.97 mM)

Bioactivity

−
Target IC50
20S proteasome:118.8±15.7 μM|26S:157±19 μM
In Vivo
Borneol significantly counteracts the process of epileptogenesis in PTZ-kindled mice. Borneol-treated animals show amelioration of biochemical alterations induced by PTZ kindling, as evidenced by decreased lipid peroxidation (LPO) and increased levels of superoxide dismutase (SOD), glutathione (GSH), and catalase (CAT). The distinct neuronal damage observed in the kindled group is suppressed by Borneol. Additionally, Borneol reduces the levels of GFAP, as indicated by reduced immunostaining. The pharmacokinetic traits of Borneol are significantly affected by the pathological damages of ischemia-reperfusion, and there are components in Xingnaojing that inhibit the absorption of Borneol.
In Vitro
In vitro, Borneol enhances the intracellular accumulation of Rho123 and facilitates the transport of P-gp substrates across the blood-brain barrier (BBB). Additionally, it downregulates the expression of mdr1a mRNA and P-gp. Borneol activates NF-κB, and the inhibition of NF-κB with MG132 and SN50 attenuates the reduction in P-gp induced by Borneol. Treatment with 10 μg/mL and 20 μg/mL Borneol transiently increases the phosphorylation of IκB expression at 30 min post-treatment. Furthermore, Borneol treatment leads to a decrease in P-gp expression in brain microvascular endothelial cells (BMECs).

Storage & Handling

−
Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

−
GABA Receptor, GABAReceptor, EndogenousMetabolite, Endogenous Metabolite, Borneol, (endo)-Borneol, (±)-Borneol, 2-Borneol, 6627-72-1

Compound Identifiers

PubChem CID
6973640 ↗

Key Properties

−
No computed properties available.

Protocol Information